Halozyme Therapeutics (HALO) PT Raised to $79 at TD Cowen

TD Cowen analyst Brendan Smith raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $79.00 (from $77.00) while maintaining a Buy rating.

The analyst comments: "Top/bottom line beat/raise in Q1 is near best-case scenario for HALO made even more impressive given broader biopharma headwinds. Strong royalties from Darzalex/Phesgo strength & Vyvgart Hytrulo's outperformance + raised FY25 guidance support new PT of $79 (+$2). We still see additional upside potential from ongoing launches, buybacks + MRK litigation, all of which reaffirm HALO as a top pick."

You May Also Be Interested In

• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• Ligand Pharma (LGND) Reiterated at Buy by Stifel After Chat With CEO, CFO
• Celcuity Inc (CELC) PT Lowered to $150 at Stifel as Gedatolisib Distribution Initiated